Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| VERTEX PHARMACEUTICALS INC / MAVRTX · Entity 2875 | EVP, Chief Scientific Officer | May 15, 2026 | May 19, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
VERTEX PHARMACEUTICALS INC / MA
Report date May 15, 2026 · Filed May 19, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 7,284 |
Reported balance
After 2026-05-15 transaction · row 1
1 source rowRow 1 · 2026-05-15 · Sale · Disposed 33 · Balance 7,284 F1: Transaction made pursuant to Dr. Bunnage's company approved trading plan under Rule 10b5-1, which was entered into on 11/26/2025. |
Filing footnotes · ownership attribution and instrument terms
F1: Transaction made pursuant to Dr. Bunnage's company approved trading plan under Rule 10b5-1, which was entered into on 11/26/2025.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| May 15, 2026 Filed May 19, 2026 20:05 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 33 | $453.45 | $14,963.85 |
DisclosureSEC source: 0000875320-26-000226 · wk-form4_1779221100.xml · nonDerivative · entry 1 Bunnage Mark E. · CIK 0002100735 · EVP, Chief Scientific Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 7,284 F1 · kind: Transaction made pursuant to Dr. Bunnage's company approved trading plan under Rule 10b5-1, which was entered into on 11/26/2025. Read SEC document |
| February 25, 2026 Filed Feb 26, 2026 23:06 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 620 | $486.35 | $301,537.00 |
DisclosureSEC source: 0000875320-26-000112 · wk-form4_1772147216.xml · nonDerivative · entry 2 Bunnage Mark E. · CIK 0002100735 · EVP, Chief Scientific Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 7,284 F1 · kind: Transaction made pursuant to Dr. Bunnage's company approved trading plan under Rule 10b5-1, which was entered into on 11/26/2025. Read SEC document |
| February 24, 2026 Filed Feb 26, 2026 23:06 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | Tax withholdingCommon Stock | 582 | $485.11 | $282,334.02 |
DisclosureSEC source: 0000875320-26-000112 · wk-form4_1772147216.xml · nonDerivative · entry 1 Bunnage Mark E. · CIK 0002100735 · EVP, Chief Scientific Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 7,904 Read SEC document |
| February 18, 2026 Filed Feb 19, 2026 21:12 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 1,182 | $473.68 | $559,889.76 |
DisclosureSEC source: 0000875320-26-000088 · wk-form4_1771535561.xml · nonDerivative · entry 4 Bunnage Mark E. · CIK 0002100735 · EVP, Chief Scientific Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 8,486 F2 · kind: Transaction made pursuant to Dr. Bunnage's company approved trading plan under Rule 10b5-1, which was entered into on 11/26/2025. Read SEC document |
| February 17, 2026 Filed Feb 19, 2026 21:12 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 2,437 | $489.46 | $1,192,814.02 |
DisclosureSEC source: 0000875320-26-000088 · wk-form4_1771535561.xml · nonDerivative · entry 3 Bunnage Mark E. · CIK 0002100735 · EVP, Chief Scientific Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 9,668 F2 · kind: Transaction made pursuant to Dr. Bunnage's company approved trading plan under Rule 10b5-1, which was entered into on 11/26/2025. Read SEC document |
| February 17, 2026 Filed Feb 19, 2026 21:12 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | Tax withholdingCommon Stock | 1,110 | $483.75 | $536,962.50 |
DisclosureSEC source: 0000875320-26-000088 · wk-form4_1771535561.xml · nonDerivative · entry 2 Bunnage Mark E. · CIK 0002100735 · EVP, Chief Scientific Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 12,105 Read SEC document |
| February 17, 2026 Filed Feb 19, 2026 21:12 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | GrantCommon Stock | 2,584 | $0.00 | $0.00 |
DisclosureSEC source: 0000875320-26-000088 · wk-form4_1771535561.xml · nonDerivative · entry 1 Bunnage Mark E. · CIK 0002100735 · EVP, Chief Scientific Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 13,215 F1 · shares: Restricted stock unit award that vests in installments beginning on February 20, 2027. Read SEC document |
| February 13, 2026 Filed Feb 18, 2026 21:32 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | Tax withholdingCommon Stock | 2,283 | $487.76 | $1,113,556.08 |
DisclosureSEC source: 0000875320-26-000068 · wk-form4_1771450339.xml · nonDerivative · entry 1 Bunnage Mark E. · CIK 0002100735 · EVP, Chief Scientific Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 10,631 Read SEC document |
| February 11, 2026 Filed Feb 12, 2026 21:56 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 2,021 | $460.43 | $930,529.03 |
DisclosureSEC source: 0000875320-26-000044 · wk-form4_1770933367.xml · nonDerivative · entry 2 Bunnage Mark E. · CIK 0002100735 · EVP, Chief Scientific Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 12,914 F1 · kind: Transaction made pursuant to Dr. Bunnage's company approved trading plan under Rule 10b5-1, which was entered into on 11/26/2025. Read SEC document |
| February 10, 2026 Filed Feb 12, 2026 21:56 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | Tax withholdingCommon Stock | 1,127 | $468.41 | $527,898.07 |
DisclosureSEC source: 0000875320-26-000044 · wk-form4_1770933367.xml · nonDerivative · entry 1 Bunnage Mark E. · CIK 0002100735 · EVP, Chief Scientific Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 14,935 Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.